Middle Molecule Removal
Middle Molecule Removal - Related Videos
11:00
Adenovirus-mediated Genetic Removal of Signaling Molecules in Cultured Primary Mouse Embryonic Fibroblasts
0 Views •
Cited by 5 •
2010
In this video we use an adenovirus carrying the Cre recombinase gene to infect primary mouse embryonic fibroblasts carrying a floxed Rac1 allele.
02:38
Molecules and Compounds
0 Views •
2020
Atoms and Molecules Everything in the universe is made up of matter, and matter is composed of a combination of elements. An atom is the smallest unit of an element that retains all properties of the element. For example, a silver coin is made up of silver atoms, and each silver atom retains the unique properties of the element — silver. Elements are pure substances consisting of identical atoms that cannot be broken down into simpler substances by chemical changes. Atomic elements contain...
07:43
Utilizing a Cranial Window to Visualize the Middle Cerebral Artery During Endothelin-1 Induced Middle Cerebral Artery Occlusion
0 Views •
Cited by 4 •
2013
This article describes a method for visualizing rat cerebral arteries through a cranial window using temporal craniectomy in order to view proximal portions of the middle cerebral artery (Figure 1). This versatile method can be combined with various techniques of drug delivery to measure cerebral artery reactivity in vivo.
06:43
Rotary Evaporation to Remove Solvent
0 Views •
2023
Source: Dr. Melanie Pribisko Yen and Grace Tang — California Institute of Technology Rotary evaporation is a technique most commonly used in organic chemistry to remove a solvent from a higher-boiling point compound of interest. The rotary evaporator, or "rotovap", was invented in 1950 by the chemist Lyman C. Craig. The primary use of a rotovap is to dry and purify samples for downstream applications. Its speed and ability to handle large volumes of solvent make rotary evaporation a preferred...
06:59
Nanomanipulation of Single RNA Molecules by Optical Tweezers
0 Views •
Cited by 13 •
2014
Optical tweezers have been used to study RNA folding by stretching individual molecules from their 5’ and 3’ ends. Here common procedures are described to synthesize RNA molecules for tweezing, calibration of the instrument, and methods to manipulate single molecules.
FAQs
Convection carries solutes across a semipermeable membrane with moving solvent, allowing transport that is not driven solely by a concentration gradient. This differs from diffusion, which moves compounds down a concentration difference. Because middle molecules are larger than conventional small dialysis toxins, adding solvent flow can improve their passage and increase removal during extracorporeal treatment.
Protein binding can limit how readily a uremic compound crosses the membrane, reducing the amount available for extracorporeal clearance. Consequently, removal cannot be predicted from molecular size alone. Evaluating protein binding alongside membrane properties and treatment dose helps explain why some peptide-like or protein-associated solutes remain difficult to remove.
Membrane properties determine which solutes can cross and how efficiently they move during treatment. A semipermeable membrane must permit appropriate transport while maintaining separation between blood and the treatment fluid. High-flux membranes are particularly relevant because they support enhanced movement of larger solutes, making membrane selection an important part of clearance design.
Hemodiafiltration combines a concentration gradient with solvent flow, using diffusion and convection together rather than relying on one transport mechanism. This dual approach can enhance movement of middle molecules across the membrane. Its importance lies in addressing solutes whose size or behavior may make clearance by conventional diffusion alone less effective.
In renal replacement therapy, clinicians can use high-flux hemodialysis or hemodiafiltration to support clearance beyond that achieved for conventional small dialysis toxins. The treatment approach must account for membrane properties and delivered dose, because these factors influence how much of the accumulated solute burden is removed during extracorporeal therapy.
Removal depends on several interacting features: the solute’s molecular size, its degree of protein binding, the membrane’s properties, and the treatment dose. These variables determine whether a compound can cross the membrane and how much transport occurs. Considering them together helps interpret differences in clearance among patients, solutes, and treatment strategies.
Accumulation of larger protein-bound or peptide-like uremic compounds may contribute to complications associated with chronic kidney disease. Improving their clearance may reduce toxin burden, although the clinical effect depends on how effectively each solute is removed. The same principles also support development of more selective extracorporeal therapies for kidney failure.